B lymphocyte proliferation is suppressed by the opioid growth factor–opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases
Authors:
- Ian S. ZagonIZIan S. Zagon
- Renee N. DonahueRDRenee N. Donahue
- Robert H. BonneauRBRobert H. Bonneau
- Patricia J. McLaughlinPMPatricia J. McLaughlin
- 1 January 2011
- journal article
- Published by Elsevier in Immunobiology
- Vol. 216 (1-2) , 173-183
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Activating systemic autoimmunity: B's, T's, and tollsCurrent Opinion in Immunology, 2009
- Novel approaches for identifying target antigens of autoreactive human B and T cellsSeminars in Immunopathology, 2009
- Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitusAutoimmunity Reviews, 2009
- Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathyAutoimmunity Reviews, 2009
- B cells in autoimmunityArthritis Research & Therapy, 2009
- The OGF–OGFr Axis Utilizes the p16INK4aand p21WAF1/CIP1Pathways to Restrict Normal Cell ProliferationMolecular Biology of the Cell, 2009
- The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancerMolecular Cancer, 2008
- The opioid–cytokine connectionJournal of Neuroimmunology, 1998
- Ultralow concentrations of proenkephalin and [met5]-enkephalin differentially affect IgM and IgG production by B cellsJournal of Neuroimmunology, 1997
- Phosphorylation of enkephalins enhances their proteolytic stabilityLife Sciences, 1996